References:
1. Matsumura, Y., et al., Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC infectious diseases, 2011. 11 (1): p. 1-9.
2. Pagano, L., et al., Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years’ experience of infection in GIMEMA centres. British journal of haematology, 2002. 117 (2): p. 379-386.
3. Caselli, D., et al., Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. The Journal of pediatrics, 2014. 164 (2): p. 389-392. e1.
4. Bucaneve, G., et al., Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New England Journal of Medicine, 2005. 353 (10): p. 977-987.
5. Neumann, S., et al., Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors. Annals of hematology, 2013. 92 (4): p. 433-442.
6. Gigliotti, F., A. Harmsen, and T. Wright, Characterization of transmission of Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice. Infection and Immunity, 2003.71 (7): p. 3852-3856.
7. Morris, A. and K.A. Norris, Colonization by Pneumocystis jirovecii and its role in disease. Clinical microbiology reviews, 2012. 25 (2): p. 297-317.
8. Vargas, S.L., et al., Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clinical Infectious Diseases, 2001. 32 (6): p. 855-861.
9. Douglas, C., Fungal β (1, 3)-D-glucan synthesis. Sabouraudia, 2001. 39 (1): p. 55-66.
10. Roth, A., et al., Light and electron microscopy study of carbohydrate antigens found in the electron-lucent layer of Pneumocystis carinii cysts. Parasitology research, 1997. 83 (2): p. 177-184.
11. Thomas, C.F. and A.H. Limper, Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nature Reviews Microbiology, 2007. 5 (4): p. 298-308.
12. Ricks, D.M., et al., Dectin immunoadhesins and pneumocystis pneumonia. Infection and immunity, 2013.81 (9): p. 3451-3462.
13. Steele, C., et al., Alveolar macrophage–mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the dectin-1 β-glucan receptor. The Journal of experimental medicine, 2003. 198 (11): p. 1677-1688.
14. Vassallo, R., J.E. Standing, and A.H. Limper, Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. The Journal of Immunology, 2000. 164 (7): p. 3755-3763.
15. Vassallo, R., et al., Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. American Journal of Respiratory Cell and Molecular Biology, 2001. 25 (2): p. 203-211.
16. Benfield, T.L., et al., Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. American journal of respiratory and critical care medicine, 1995. 151 (4): p. 1058-1062.
17. Chen, W., E.A. Havell, and A.G. Harmsen, Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infection and immunity, 1992. 60 (4): p. 1279-1284.
18. Phair, J., et al., The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. New England journal of medicine, 1990.322 (3): p. 161-165.
19. Shellito, J., et al., A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. The Journal of clinical investigation, 1990.85 (5): p. 1686-1693.
20. Avino, L.J., S.M. Naylor, and A.M. Roecker, Pneumocystis jirovecii pneumonia in the non–HIV-infected population. Annals of Pharmacotherapy, 2016. 50 (8): p. 673-679.
21. Iriart, X., et al., Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. American journal of transplantation, 2015. 15 (1): p. 190-199.
22. Taplitz, R.A., et al., Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. Journal of Clinical Oncology, 2018. 36 (30): p. 3043-3054.
23. Yale, S.H. and A.H. Limper. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy. in Mayo Clinic Proceedings. 1996. Elsevier.
24. Park, J.W., et al., Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Annals of the rheumatic diseases, 2018. 77 (5): p. 644-649.
25. Huang, Y.-C., et al., Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Annals of hematology, 2011. 90 (10): p. 1145-1151.
26. Cordonnier, C., et al., Fifth European Conference on Infections in Leukemia (ECIL-5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother, 2016. 71 (9): p. 2379-2385.
27. Kalin, M., et al., Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients. Annals of hematology, 2010. 89 (5): p. 523-525.
28. Haeusler, G.M., et al., Late‐onset P neumocystis jirovecii pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. European journal of haematology, 2013. 91 (2): p. 157-163.
29. De Vos, F.Y., et al., Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. Critical reviews in oncology/hematology, 2013. 85 (3): p. 373-382.
30. Sepkowitz, K.A., Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clinical infectious diseases, 2002.34 (8): p. 1098-1107.
31. Kaplan, J.E., et al., Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clinical infectious diseases, 2000.30 (Supplement_1): p. S5-S14.
32. Moher, D., et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine, 2009. 6 (7): p. e1000097.
33. Chang, H., et al., Pneumocystis jirovecii pneumonia in patients with acute myeloid leukaemia. Internal medicine journal, 2018. 48 (1): p. 81-83.
34. Roux, A., et al., Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerging infectious diseases, 2014. 20 (9): p. 1490.
35. Otsuka, M., et al., Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia. Intern Med, 1997.36 (10): p. 705-8.
36. Ong, Y.L. and F.G. Jones, A cluster of suspected Pneumocystis carinii Pneumonia following intensive chemotherapy in a Belfast haematology unit. Ulster Med J, 1998.67 (2): p. 104-9.
37. Chowdhary, V., et al., Sweet’s syndrome and Pneumocystis carinii pneumonia: two sequelae of low‐dose cytosine arabinoside therapy in a patient with acute myeloid leukemia. European journal of haematology, 2000. 65 (1): p. 72-73.
38. Theron, J., et al., A 21-year-old patient with acute myeloid leukemia and bilateral pulmonary infiltrates. Respiration, 2001. 68 (6): p. 649-57.
39. Cooley, L., et al., Consensus guidelines for diagnosis, prophylaxis and management of P neumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Internal medicine journal, 2014. 44 (12b): p. 1350-1363.
40. Maertens, J., et al., 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother, 2016. 71 (9): p. 2397-2404.
41. Toma, A., et al., Infections in myelodysplastic syndromes. Haematologica, 2012. 97 (10): p. 1459.
42. Roblot, F., et al., Risk factors analysis for Pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia. Scandinavian journal of infectious diseases, 2004. 36 (11-12): p. 848-854.
43. Obeid, K.M., et al., Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders. Clinical Lymphoma Myeloma and Leukemia, 2012. 12 (1): p. 66-69.
44. Arad-Cohen, N., J.M. Rowe, and Y. Shachor-Meyouhas, Pharmacological prophylaxis of infection in pediatric acute myeloid leukemia patients. Expert opinion on pharmacotherapy, 2020. 21 (2): p. 193-205.
45. Antoine, R., B. Caroline, and V. François, All Patients with Leukemia Are Not Equally at Risk of Contracting Pneumocystis jirovecii Pneumonia. The American journal of medicine, 2015. 128 (1): p. e9.
46. Lemez, P., et al., Successful prevention of Pneumocystis carinii infection with 1,920 mg of trimethoprim-sulfamethoxazole daily in patients with malignant hematopoietic diseases. Vnitrni lekarstvi, 1995. 41 (10): p. 688-691.
47. Drgona, L., et al., ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clinical Microbiology and Infection, 2018. 24 : p. S83-S94.
48. Castaigne, S., et al., Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. The Lancet, 2012. 379 (9825): p. 1508-1516.
Figure 1. Flow chart of study selection for inclusion in the systematic review.
Table 1 . Characteristic of included studies.